1989 Breakthrough in Schizophrenia Treatment

Printer-friendly versionPrinter-friendly version
Herbert Y. Meltzer, M.D. discovers clozapine works for treatment-resistant schizophrenia patients and to help reduce suicide
Herbert Y. Meltzer, M.D.

In our second year of grant-giving, 1988, Dr. Herbert Meltzer received a NARSAD Distinguished Investigator Grant to test his idea that clozapine might be a good option as a “second generation” antipsychotic medication in patients with treatment-resistant schizophrenia. Clozapine was approved for use in patients with resistant schizophrenia in 1989 by the FDA and led to the development of a new class of “atypical” antipsychotics that effectively treat millions of patients today.

In the early 2000s, Dr. Meltzer further demonstrated that clozapine can also be used to reduce the risk of suicide in patients with schizophrenia.

Read article in Breakthroughs 2008.

Read article from Vanderbilt University.

Read an abstract about this research from Psychopharmocology.

Read an abstract about this research from the European Journal of Pharmocology.

Read these recovery stories from issues of The Quarterly highlighting the significant impact of Clozapine:

 

Add new comment

comments

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Please note that researchers cannot give specific recommendations or advice about treatment; diagnosis and treatment are complex and highly individualized processes that require comprehensive face-to- face assessment. Please visit our "Ask an Expert" section to see a list of Q & A with NARSAD Grantees.
By submitting this form, you accept the Mollom privacy policy.